 |
|
Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences
Narender Goel, Deepika Jain, Danny B. Haddad, Divya Shanbhogue
J Stroke. 2020;22(3):306-316. Published online 2020 Sep 29 DOI: https://doi.org/10.5853/jos.2020.01886
|
|
Citations to this article as recorded by
 When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer
Panteleimon E. Papakonstantinou, Vasiliki Kalogera, Dimitrios Charitos, Dimitrios Polyzos, Dimitra Benia, Athina Batsouli, Konstantinos Lampropoulos, Sotirios Xydonas, Dhiraj Gupta, Gregory Y.H. Lip
Blood Reviews.2024; 65: 101171. CrossRef Cerebrovascular Disease Hospitalization Rates in End-Stage Kidney Disease Patients with Kidney Transplant and Peripheral Vascular Disease: Analysis Using the National Inpatient Sample (2005–2019)
Tyler John Canova, Rochell Issa, Patrick Baxter, Ian Thomas, Ehab Eltahawy, Obi Ekwenna
Healthcare.2024; 12(4): 454. CrossRef Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients
Zeeba Saeed, Vittorio Sirolli, Mario Bonomini, Sabina Gallina, Giulia Renda
International Journal of Molecular Sciences.2024; 25(16): 8705. CrossRef Kidney Function and the Use of Vitamin K Antagonists or Direct Oral Anticoagulants in Atrial Fibrillation
Dolina Gencheva
Journal of Cardiovascular Emergencies.2023; 9(3): 49. CrossRef The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis
Jerahmeel Aleson L. Mapili, Lloyd Christopher S. Lim, Bianca M. Velando, Jaime Alfonso M. Aherrera
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies
Konstantinos Zagoridis, Lazaros Karatisidis, Theodoros Mprotsis, Aikaterini Pentidou, Zoi Bezirgianidou, Christina Misidou, Emmanouil Spanoudakis
Thrombosis Research.2023; 231: 17. CrossRef Use of Non-Vitamin K Dependent Oral Anticoagulant in Ischemic Stroke
Hyungjong Park, Joonsang Yoo
Journal of the Korean Neurological Association.2022; 40(1): 1. CrossRef S2k-Leitlinie: Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke (TIA) – Teil 1 und Teil 2
Gerhard F. Hamann, D. Sander, Armin Grau, J. Röther
DGNeurologie.2022; 5(5): 369. CrossRef Diabetes und kardiovaskuläre Ereignisse
Harald Darius
Diabetes aktuell.2022; 20(05): 223. CrossRef Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
Wenhao Li, Yanxia Zhou, Siqi Chen, Dewang Zeng, Haidong Zhang
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef Choosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologist
Clarisse Roux, Kristelle Verollet, Julien Prouvot, Camelia Prelipcean, Emilie Pambrun, Olivier Moranne
Journal of Nephrology.2022; 36(2): 521. CrossRef Antithrombotic therapy in diabetes: which, when, and for how long?
Ramzi A Ajjan, Noppadol Kietsiriroje, Lina Badimon, Gemma Vilahur, Diana A Gorog, Dominick J Angiolillo, David A Russell, Bianca Rocca, Robert F Storey
European Heart Journal.2021; 42(23): 2235. CrossRef Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
Giovanni Luca Botto, Pietro Ameri, Raffaele De Caterina
Journal of Clinical Medicine.2021; 10(13): 2866. CrossRef Hemoperitoneum After Cardiopulmonary Resuscitation in Peritoneal Dialysis Patients: A Tale of Two Cases Narender Goel, Danny B Haddad, Deepika Jain
International Journal of Nephrology and Renovascular Disease.2020; Volume 13: 379. CrossRef
|